<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03431584</url>
  </required_header>
  <id_info>
    <org_study_id>CHD 046-17</org_study_id>
    <nct_id>NCT03431584</nct_id>
  </id_info>
  <brief_title>Effects on the Pain of an Infiltration by Acid Hyaluronic Association and Corticoids Versus Only Corticoids in the Rhizarthrosis.</brief_title>
  <acronym>RHIZ'ART</acronym>
  <official_title>Effects on the Pain of an Infiltration by Acid Hyaluronic Association and Corticoids Versus Only Corticoids in the Rhizarthrosis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Departemental Vendee</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Departemental Vendee</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The rhizarthrosis, or the degenerative osteoarthritis of the trapezo-metacarpal joint, is a
      frequent degenerative osteoarthritis.

      The treatment associates not pharmacological measures, such as resting relative of the joint,
      the orthosis of rest, glazing and pharmacological measures such analgesic, anti-inflammatory
      not steroidal per bones or premises, even infiltrations cortisone or by hyaluronic acid.

      No study has, for the moment, tested the interest of the combination of cortisone and
      hyaluronic acid in rhizarthrosis. In view of the current publications, we propose to carry
      out a study on two arms, with corticosteroids in reference arm; the experimental arm is the
      combination of hyaluronic acid and cortisone.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">May 11, 2018</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain</measure>
    <time_frame>3 month post infiltration</time_frame>
    <description>Analogical visual scale of pain (VAS) To 0mm (no pain) form 100mm (maximum pain imaginable)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Rhizarthrosis</condition>
  <arm_group>
    <arm_group_label>corticosteroids</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>corticosteroids and hyaluronic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>infiltration corticosteroids</intervention_name>
    <description>infiltration corticosteroids</description>
    <arm_group_label>corticosteroids</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>infiltration of corticosteroids and hyaluronic acid</intervention_name>
    <description>infiltration of corticosteroids and hyaluronic acid</description>
    <arm_group_label>corticosteroids and hyaluronic acid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults, ≥ 40 years

          -  Pain located at the root of the thumb (near the wrist) and awakened by direct pressure
             and movement

          -  Pain resistant to well-conducted medical treatment, with analgesics, NSAIDs, icing
             with pain (analog visual scale) ≥ 4 for more than 3 months

          -  Radiological findings (kapandji face + profile incidence) typical of rhizarthrosis,
             stage II or III of Eaton and Litter, with at least 2 of the following 5 radiological
             elements observed on the trapeziometacarpal joint:

               -  marginal osteophyte

               -  pinching of the joint space

               -  sclerosis of the subchondral space

               -  subchondral kyst

               -  absence of osteopenia

          -  Patient with the ability to understand the protocol and signed informed consent

          -  Patient receiving social security

        Exclusion Criteria:

          -  Known allergy to any of the products (corticosteroids or hyaluronic acid) including
             its excipients (methyl parahydroxybenzoate, propyl parahydroxybenzoate, benzyl
             alcohol)

          -  Change of analgesic treatment within 4 weeks before inclusion.

          -  Patients with symptomatic bilateral rhizarthrosis

          -  Scaphoid-trapezial arthrosis

          -  Local or general infection

          -  Severe coagulation disorders, ongoing anticoagulant therapy

          -  severe and / or uncontrolled hypertension

          -  Earlier local surgery

          -  Associated inflammatory rheumatism

          -  Tendinopathy of De Quervain, thumb to jump associated

          -  Infiltrations earlier than 6 months

          -  Diabetes imbalanced

          -  Live vaccines

          -  Severe water and / or sodium retention (hypernatremia), particularly in cases of heart
             failure, decompensated liver failure (edema and ascites failure)

          -  Pregnant or lactating women

          -  Immunocompromised or hemodialysis patients

          -  Patients under guardianship, trusteeship, or deprived of liberty

          -  Patients participating in another clinical research protocol involving a drug or
             medical device

          -  Patients unable to follow the protocol, according to the judgment of the investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lucie AUZANNEAU</last_name>
    <phone>0251446380</phone>
    <phone_ext>+33</phone_ext>
    <email>lucie.auzanneau@chd-vendee.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHD Vendée</name>
      <address>
        <city>La Roche-sur-Yon</city>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Grégoire CORMIER, PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Le Mans</name>
      <address>
        <city>Le Mans</city>
        <zip>72037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Amélie DENIS, PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Benoit LE GOFF, PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 6, 2018</study_first_submitted>
  <study_first_submitted_qc>February 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 13, 2018</study_first_posted>
  <last_update_submitted>May 7, 2018</last_update_submitted>
  <last_update_submitted_qc>May 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

